Cabaletta: Preliminary Phase II/III data

Preliminary data from 11 evaluable Israeli patients with OPMD in the international Phase II/III HOPEMD trial showed that once-weekly 30 g IV Cabaletta was well tolerated with no treatment-related serious adverse events reported. There were no significant changes in blood pressure, heart rate and electrocardiogram, glucose tolerance and insulin blood levels, liver and renal functions, blood count and other vital and biochemical parameters. Based on the safety data, an IRB approved continuation in Israel into the next phase of the trial. ...